83635-12-5

Basic information

• Product Name: Butyl Cyclopropanesulfonate
• Synonyms: Butyl Cyclopropanesulfonate;Cyclopropanesulfonic Acid Butyl Ester
• CAS NO: 83635-12-5
• Molecular Formula: C₇H₁₄O₃S
• Molecular Weight: 178.24926
• Product Categories: Intermediates;Miscellaneous Reagents;Sulfur & Selenium Compounds
• Mol File: 83635-12-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 296.182°C at 760 mmHg
• Flash Point: 132.926°C
• Appearance: /
• Density: 1.167g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.474
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform, Dichloromethane, Ethyl Acetate
• CAS DataBase Reference: Butyl Cyclopropanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: Butyl Cyclopropanesulfonate(83635-12-5)
• EPA Substance Registry System: Butyl Cyclopropanesulfonate(83635-12-5)

Safety Data

• Hazardous Substances Data: 83635-12-5(Hazardous Substances Data)

Usage

Chemical Properties

Colourless Oil

InChI:InChI=1/C7H14O3S/c1-2-3-6-10-11(8,9)7-4-5-7/h7H,2-6H2,1H3

Upstream product

• 146475-47-0 1-butyl 3-chloro-1-propanesulfonate 
• 139631-62-2 cyclopropanesulfonyl chloride 
• 71-36-3 butan-1-ol 
• 83634-86-0 butyl 3-(dimethylamino)propanesulfonate 

Downstream Products

• 1399317-16-8 butyl 1-((benzyloxy)methyl)cyclopropane-1-sulfonate 

Relevant articles and documents

SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS

The present application relates to a series of substituted imidazo[1,2-a]pyridine compounds of formula (I), pharmaceutically acceptable salts, pharmaceutically acceptable solvates or stereoisomers thereof, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.

COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF

This invention concerns combinations of inhibitors of MEK, Raf protein kinases, and other kinases including VEGFR1-3 and PDGFR-β. This invention also concerns pharmaceutical compositions comprising the compounds described herein and methods of use of the compounds and compositions described herein, including the use in the treatment and/or prevention of cancer and other hyperproliferative disorders.

N-(ARYLAMINO)-SULFONAMIDE INHIBITORS OF MEK

This invention concerns N-(2-arylamino) aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.